LABNEW fluctuates 32.7% in 24 hours: Whale accumulation drives rebound followed by correction
Bitget Pulse2026/05/16 16:02Volatility Brief
LABNEW (LAB) surged rapidly from a 24-hour low of $3.91113 to a peak of $5.18852, currently trading at $4.73782, with a range of 32.7%. During this period, trading volume expanded significantly, indicating active capital inflows followed by partial profit-taking.
Analysis of Unusual Price Movement
- Large whale wallet withdrawals drive rebound: On-chain monitoring shows several new wallets withdrew about 30% of circulating supply (about 100 million LAB) from exchanges, with an average cost around $4.90, directly triggering a strong price rebound from the lows.
- High trading volume accompanied by net inflows: 24-hour trading volume soared to the $200M-$238M range, with substantial net capital inflow amplifying volatility.
- Subsequent correction pressure emerges: Some funds took profits at higher levels, while market concerns over potential manipulation intensified, causing prices to retreat from the highs.
Market Views and Outlook
The community and analysts generally maintain a cautiously optimistic sentiment, believing whale accumulation provides short-term support, but low liquidity and concentrated holdings may trigger sharp volatility. Mainstream opinions recommend closely monitoring subsequent large on-chain transfers and exchange data; without further positive developments, short-term price action may remain volatile at high levels. Some analysts warn of potential "pump-dump" risks and advise strict risk management.
Note: This analysis is automatically generated by AI based on public data and on-chain monitoring, for information reference only.Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
SUI SuperTrend Flips to Buy — Macro Shift From Bearish to Bullish Begins

Novo Nordisk (NVO.US) unveils $23 billion pipeline blueprint, but the market isn't buying it! Investors ask, "How to turn the tide against adversity?"
After being surpassed by Eli Lilly in the obesity market, Novo Nordisk failed to present a concrete turnaround plan to CEO Mike Doustdal, disappointing investors. The company has pledged to launch more than five blockbuster drugs in the coming years and achieve over $23 billion in new sales, but the press conference lacked details on how to drive growth.

STONK hits new highs after erasing 27% crash

25 Days, Four Launches in Sight! Rocket Lab (RKLB.US) Accelerates Rocket Launches to Advance Its Ambitious "Space AI Infrastructure" Goals
After another successful mission, Rocket Lab's 97th Electron rocket is now positioned at the launch pad. This flight will be Rocket Lab's fourth launch in 25 days and its 18th launch in 2026.